2020
DOI: 10.1016/j.ijbiomac.2020.04.251
|View full text |Cite
|
Sign up to set email alerts
|

Mucoadhesive cholesterol-chitosan self-assembled particles for topical ocular delivery of dexamethasone

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
19
0

Year Published

2020
2020
2025
2025

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 30 publications
(19 citation statements)
references
References 33 publications
0
19
0
Order By: Relevance
“…The washed cells were then resuspended in 50 µL fresh PBS, stained with mouse antibodies against human CD54 (Beckman Coulter Inc., Indianapolis, IN, USA) in the dark for 15 min, and washed again. Finally, the washed cells were resuspended in 100 µL fresh PBS and stained for 5 min with 250 nM PO-PRO-1 iodide (Invitrogen, Thermo Fisher Scientific, USA) and 3 µM DRAQ7 (Beckman Coulter Inc., USA), as described previously [17]. At least 10,000 single THP-1 cells per each sample were acquired.…”
Section: Anti-inflammatory Activity Of the Succs-dex Conjugatesmentioning
confidence: 99%
See 1 more Smart Citation
“…The washed cells were then resuspended in 50 µL fresh PBS, stained with mouse antibodies against human CD54 (Beckman Coulter Inc., Indianapolis, IN, USA) in the dark for 15 min, and washed again. Finally, the washed cells were resuspended in 100 µL fresh PBS and stained for 5 min with 250 nM PO-PRO-1 iodide (Invitrogen, Thermo Fisher Scientific, USA) and 3 µM DRAQ7 (Beckman Coulter Inc., USA), as described previously [17]. At least 10,000 single THP-1 cells per each sample were acquired.…”
Section: Anti-inflammatory Activity Of the Succs-dex Conjugatesmentioning
confidence: 99%
“…For this reason, an intravitreal dosage form must have a prolonged release profile of active pharmaceutical substances over several months while still maintaining the drug concentration at an adequate therapeutic level [8,11,12]. Current intravitreal drugs include implants (e.g., FDA approved Ozurdex [13]) and various types of polymeric nanoparticles, but many of these implants and nanoparticles consist of nondegradable polymers, and this limits their wide clinical application for controlled drug release [2,3,[14][15][16][17]. The use of various nanoparticles for retinal delivery does not ensure the desired months-long release profile and can also lead to increased intraocular pressure and visual impairment [11].…”
Section: Introductionmentioning
confidence: 99%
“…These nanocarriers performed better in terms of drug release behavior and antiinflammatory effects in the guinea pig model compared with micronized gel (Alqurshi et al, 2019). Several studies have attempted to modify polysaccharides simply to obtain various non-covalent interactions (Dubashynskaya N. V. et al, 2020;Liu C.H. et al, 2020).…”
Section: Typical Ocular Polysaccharide-based Nanocarriers and Novel Design Strategiesmentioning
confidence: 99%
“…Among natural polymers, natural polysaccharides are widely used because of their diverse functions including biosafety, good tolerance, superior bioavailability and biological activities. More and more evidence indicates that polysaccharide-based nanocarriers have received considerable attention for clinical practice [ 10 , 11 ].…”
Section: Introductionmentioning
confidence: 99%